Gain Therapeutics Inc
NASDAQ:GANX
Gain Therapeutics Inc
NASDAQ:GANX
Price:
2.9 USD
1.75%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
GANX
stock under the Base Case scenario is
0.08
USD.
Compared to the current market price of 2.9 USD,
Gain Therapeutics Inc
is
Overvalued by 97%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GANX
Relative Value
Base Case
0.08
USD
Overvaluation 97%
Valuation Multiples
Multiples Across Competitors
GANX Competitors Multiples
Gain Therapeutics Inc Competitors
Gain Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Gain Therapeutics Inc
NASDAQ:GANX
|
47m USD | 851.7 | -2.1 | -1.4 | -1.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161.1B USD | 5.5 | 42.8 | 18.2 | 30 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.9B USD | 8.2 | 27.7 | 22.4 | 24.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.7B USD | 10.7 | 29.2 | 23.4 | 24.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.5 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.4B USD | 9 | -7.8 | -8.4 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.3 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.1T KRW | 18.4 | 74.9 | 45.8 | 63.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
